- Home
- USCB vs SLN Comparison
USCB vs SLN Comparison
Compare USCB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- SLN
- Stock Information
- Founded
- USCB 2002
- SLN 1994
- Country
- USCB United States
- SLN United Kingdom
- Employees
- USCB N/A
- SLN N/A
- Industry
- USCB Major Banks
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- SLN Health Care
- Exchange
- USCB Nasdaq
- SLN Nasdaq
- Market Cap
- USCB 316.4M
- SLN 299.4M
- IPO Year
- USCB 2021
- SLN N/A
- Fundamental
- Price
- USCB $17.34
- SLN $4.81
- Analyst Decision
- USCB Buy
- SLN Buy
- Analyst Count
- USCB 3
- SLN 5
- Target Price
- USCB $20.33
- SLN $32.60
- AVG Volume (30 Days)
- USCB 16.8K
- SLN 61.8K
- Earning Date
- USCB 10-30-2025
- SLN 08-07-2025
- Dividend Yield
- USCB 2.30%
- SLN N/A
- EPS Growth
- USCB 67.08
- SLN N/A
- EPS
- USCB 1.47
- SLN N/A
- Revenue
- USCB $88,094,000.00
- SLN $27,169,000.00
- Revenue This Year
- USCB $26.38
- SLN N/A
- Revenue Next Year
- USCB $4.39
- SLN N/A
- P/E Ratio
- USCB $11.83
- SLN N/A
- Revenue Growth
- USCB 32.06
- SLN 22.28
- 52 Week Low
- USCB $13.85
- SLN $1.97
- 52 Week High
- USCB $21.86
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- USCB 55.15
- SLN 34.88
- Support Level
- USCB $17.10
- SLN $4.91
- Resistance Level
- USCB $17.98
- SLN $5.34
- Average True Range (ATR)
- USCB 0.52
- SLN 0.48
- MACD
- USCB 0.06
- SLN -0.05
- Stochastic Oscillator
- USCB 73.38
- SLN 0.71
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.